Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

Colorectal cancer rates in the U.S. are moving in two very different directions, according to a report released from the American Cancer Society.

March 06, 2026

Vol.52 No.09

In Brief

Bob Purcell named chief communications officer at PICI

Bob Purcell was named chief communications officer at The Parker Institute for Cancer Immunotherapy.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

In Brief

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

A WVU Cancer Institute team has achieved a global medical first in a clinical trial examining the efficacy of subcutaneous blinatumomab (Blincyto) in treating one of the rarest and most aggressive forms of leukemia.

February 20, 2026

Vol.52 No.07

Guest Editorial

Science is winning the war on cancer—CMS shouldn’t disarm

In 1971, the National Cancer Act declared a war on cancer, making it a national priority to attack this scourge of diseases.

February 13, 2026

Vol.52 No.06

By John M. O’Brien

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

YOU MAY BE INTERESTED IN

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

Bob Purcell named chief communications officer at PICI

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

Science is winning the war on cancer—CMS shouldn’t disarm

Renew today!

Subscriber content

Never miss an issue!

Login